JP2012065675A - インスリンを補った乳児用調製乳 - Google Patents
インスリンを補った乳児用調製乳 Download PDFInfo
- Publication number
- JP2012065675A JP2012065675A JP2012001306A JP2012001306A JP2012065675A JP 2012065675 A JP2012065675 A JP 2012065675A JP 2012001306 A JP2012001306 A JP 2012001306A JP 2012001306 A JP2012001306 A JP 2012001306A JP 2012065675 A JP2012065675 A JP 2012065675A
- Authority
- JP
- Japan
- Prior art keywords
- insulin
- infant formula
- infant
- amino acid
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims abstract description 178
- 102000004877 Insulin Human genes 0.000 title claims abstract description 90
- 108090001061 Insulin Proteins 0.000 title claims abstract description 90
- 229940125396 insulin Drugs 0.000 title claims abstract description 89
- 235000013350 formula milk Nutrition 0.000 title claims abstract description 49
- 238000000034 method Methods 0.000 claims abstract description 21
- 239000000843 powder Substances 0.000 claims abstract description 12
- 239000013589 supplement Substances 0.000 claims abstract description 12
- 239000007788 liquid Substances 0.000 claims abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 4
- 101000976075 Homo sapiens Insulin Proteins 0.000 claims description 18
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 claims description 17
- 235000015872 dietary supplement Nutrition 0.000 claims description 16
- 235000013336 milk Nutrition 0.000 claims description 14
- 239000008267 milk Substances 0.000 claims description 14
- 210000004080 milk Anatomy 0.000 claims description 14
- 150000001413 amino acids Chemical group 0.000 claims description 10
- 235000010469 Glycine max Nutrition 0.000 claims description 7
- 244000068988 Glycine max Species 0.000 claims description 4
- 235000005911 diet Nutrition 0.000 claims description 4
- 230000037213 diet Effects 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 239000012264 purified product Substances 0.000 claims 1
- 235000012041 food component Nutrition 0.000 abstract 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 19
- 235000020256 human milk Nutrition 0.000 description 13
- 210000004251 human milk Anatomy 0.000 description 12
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 8
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 8
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 229960003080 taurine Drugs 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- -1 Soy protein isolate Substances 0.000 description 3
- 230000001363 autoimmune Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229960003284 iron Drugs 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 229940091250 magnesium supplement Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 2
- 101001011741 Bos taurus Insulin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102000014171 Milk Proteins Human genes 0.000 description 2
- 108010011756 Milk Proteins Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- FYGDTMLNYKFZSV-DZOUCCHMSA-N alpha-D-Glcp-(1->4)-alpha-D-Glcp-(1->4)-D-Glcp Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)O[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-DZOUCCHMSA-N 0.000 description 2
- IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 2
- 229960004203 carnitine Drugs 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000023011 digestive tract development Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 235000021129 infant diet Nutrition 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 229960004452 methionine Drugs 0.000 description 2
- 235000021239 milk protein Nutrition 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 235000020185 raw untreated milk Nutrition 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 229940071440 soy protein isolate Drugs 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 235000021119 whey protein Nutrition 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000020192 tolerance induction in gut-associated lymphoid tissue Effects 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pediatric Medicine (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Dairy Products (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
【解決手段】本発明は、複数種の栄養補給成分と、インスリンサプリメントとを含有する粉末または液状の乳児用調製乳に関し、さらに、乳児に食餌を摂取させる方法であって、複数種の栄養補給成分と、インスリンサプリメントとを含有する乳児用調製乳粉末を水に溶解させることによって前記複数種の栄養補給成分と前記インスリンサプリメントとを含有する溶液を得るステップと、前記溶液を前記乳児に摂取させるステップと、を含む方法に関する。
【選択図】なし
Description
of the Rambam Medical Center,Haifa,Israelにおける研究を含む)によると、1型糖尿病患者は、母乳を摂取した期間が3ヶ月間未満であり、かつ生後3ヶ月未満で牛乳蛋白に接触していた傾向がより高かった(非特許文献3)。さらに、抗体試験とリンパ球活性試験とによって、IDDM患者の免疫系が牛乳蛋白を認識することが実証された(非特許文献11)。上記データは、食餌と、経口投与される蛋白質とが、自己免疫性糖尿病の発現に重要な関わりを持つことを強調するものである。
乳サンプルおよびインスリン測定:人間の母乳サンプルは、正常な妊娠期間を経て分娩した、分娩後2日目以上30日目以内の母親から収集した。牛乳サンプルは、貯蔵されている未加工の市販の乳から採取した。牛乳調製乳は製造業者の指示に従って調製した。全サンプルをポリプロピレン管内で−20℃に保管した。乳サンプルを、PBS(KH2PO4 10mM、NaCl 0.15M、pH7.4)を用いて希釈することにより脂肪を含まない下清みを得、次いで100000gで60分間遠心分離した。透明な下清みを吸引し、−20℃で保管した。インスリン濃度は、ヒトインスリンを基準物質とし、市販のキット(Bio Data,Sorin)を用いてラジオイムノアッセイにて決定した。
表1に示すように、人乳のインスリン濃度(約42μU/ml)は、市販の未加工牛乳(約17μU/ml)や乳児用調製乳(約4〜12μU/ml)に比し著しく高い。乳児用調製乳のインスリンレベルは非常に低く、このレベルはネガティブコントロール溶液(0.5%ウシ血清アルブミン溶液、約6μU/ml)で記録されたレベルに近い。
該調製乳は以下の成分を含有する:ラクト−ス、野菜油、脱脂乳粉末、ホエー蛋白濃縮物、ナトリウム、カルシウム、リン、カリウム、塩化物、鉄、マグネシウム、タウリン、ビタミン類およびインスリン。
該調製乳は以下の成分を含有する:ブドウ糖シロップ、野菜油、大豆蛋白単離物、ショ糖、マルトオリゴ糖、ナトリウム、カルシウム、リン、カリウム、塩化物、鉄、マグネシウム、ビタミン類、メチオニン、タウリン、カルニチン、微量元素およびインスリン。
Claims (24)
- 複数種の栄養補給成分と、インスリンサプリメントとを含有する、粉末状または液状の乳児用調製乳であって、前記乳児用調製乳を乳児が摂取することによって前記乳児が糖尿病を発症する可能性が低下する、乳児用調製乳。
- 前記インスリンがヒトインスリンのアミノ酸配列を含む、請求項1に記載の乳児用調製乳。
- 前記インスリンが組換えインスリンである、請求項1に記載の乳児用調製乳。
- 前記インスリンがヒトインスリンのアミノ酸配列を含む、請求項3に記載の乳児用調製乳。
- 前記インスリンが合成インスリンである、請求項1に記載の乳児用調製乳。
- 前記インスリンがヒトインスリンのアミノ酸配列を含む、請求項5に記載の乳児用調製乳。
- 前記インスリンが天然インスリン精製物である、請求項1に記載の乳児用調製乳。
- 前記インスリンがヒトインスリンのアミノ酸配列を含む、請求項7に記載の乳児用調製乳。
- 前記インスリンが生物学的に活性なものである、請求項1に記載の乳児用調製乳。
- 前記インスリンの濃度範囲が粉末100gに対して約25000〜75000μUまたは溶液100mlに対して3000〜10000μUである、請求項1に記載の乳児用調製乳。
- 前記複数種の栄養補給成分のうち少なくとも数種が乳由来である、請求項1に記載の乳児用調製乳。
- 前記複数種の栄養補給成分のうち少なくとも数種が大豆由来である、請求項1に記載の乳児用調製乳。
- 乳児に食餌を摂取させる方法であって、複数種の栄養補給成分と、インスリンサプリメントとを含有する乳児用調製乳粉末を水に溶解し、前記複数種の栄養補給成分と前記インスリンサプリメントとを含有する溶液を得るステップと、前記溶液を前記乳児に摂取させることによって、前記乳児が糖尿病を発症する可能性を低下させるステップと、を含む方法。
- 前記インスリンがヒトインスリンのアミノ酸配列を含む、請求項13に記載の方法。
- 前記インスリンが組換えインスリンである、請求項13に記載の方法。
- 前記インスリンがヒトインスリンのアミノ酸配列を有する、請求項15に記載の方法。
- 前記インスリンが合成インスリンである、請求項13に記載の方法。
- 前記インスリンがヒトインスリンのアミノ酸配列を有する、請求項17に記載の方法。
- 前記インスリンが天然インスリン精製物である、請求項13に記載の方法。
- 前記インスリンがヒトインスリンのアミノ酸配列を有する、請求項19に記載の方法。
- 前記インスリンが生物的に活性なものである、請求項13に記載の方法。
- 前記インスリンの濃度範囲が、前記粉末100gに対して約25000〜75000μUまたは前記溶液100mlに対して3000〜10000μUである、請求項13に記載の方法。
- 前記複数種の栄養補給成分のうち少なくとも数種が乳由来である、請求項13に記載の方法。
- 前記複数種の栄養補給成分のうち少なくとも数種が大豆由来である、請求項13に記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9090998A | 1998-06-05 | 1998-06-05 | |
US09/090,909 | 1998-06-05 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000551812A Division JP2002516880A (ja) | 1998-06-05 | 1999-06-03 | インスリンを補った乳児用調製乳 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012065675A true JP2012065675A (ja) | 2012-04-05 |
JP5188631B2 JP5188631B2 (ja) | 2013-04-24 |
Family
ID=22224914
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000551812A Pending JP2002516880A (ja) | 1998-06-05 | 1999-06-03 | インスリンを補った乳児用調製乳 |
JP2012001306A Expired - Lifetime JP5188631B2 (ja) | 1998-06-05 | 2012-01-06 | インスリンを補った乳児用調製乳 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000551812A Pending JP2002516880A (ja) | 1998-06-05 | 1999-06-03 | インスリンを補った乳児用調製乳 |
Country Status (10)
Country | Link |
---|---|
US (1) | US6365177B1 (ja) |
EP (1) | EP1083930B1 (ja) |
JP (2) | JP2002516880A (ja) |
AT (1) | ATE413889T1 (ja) |
AU (1) | AU762626B2 (ja) |
CA (1) | CA2334222C (ja) |
DE (1) | DE69939900D1 (ja) |
ES (1) | ES2320715T3 (ja) |
IL (1) | IL140089A (ja) |
WO (1) | WO1999062558A1 (ja) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004112494A2 (en) | 2003-06-20 | 2004-12-29 | Nutrinia Ltd. | Bioactive compounds protection method and compositions containing the same |
MX2009008347A (es) | 2007-02-06 | 2009-10-19 | Lixte Biotechnology Holdings I | Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso. |
RU2524423C2 (ru) | 2008-01-09 | 2014-07-27 | Санофи-Авентис Дойчланд Гмбх | Новые производные инсулина с чрезвычайно замедленным профилем время/действие |
US8227473B2 (en) | 2008-08-01 | 2012-07-24 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
US8498729B2 (en) | 2008-08-29 | 2013-07-30 | Smp Logic Systems Llc | Manufacturing execution system for use in manufacturing baby formula |
LT2349324T (lt) | 2008-10-17 | 2017-12-27 | Sanofi-Aventis Deutschland Gmbh | Insulino ir glp-1 agonisto derinys |
MY159865A (en) * | 2009-07-06 | 2017-02-15 | Sanofi Aventis Deutschland | Aqueous insulin preparations containing methionine |
CN102711804B (zh) | 2009-11-13 | 2015-09-16 | 赛诺菲-安万特德国有限公司 | 包含glp-1激动剂和甲硫氨酸的药物组合物 |
CA2780460C (en) | 2009-11-13 | 2018-09-04 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine |
RU2546520C2 (ru) | 2010-08-30 | 2015-04-10 | Санофи-Авентис Дойчланд Гмбх | Применение ave0010 для производства лекарственного средства для лечения сахарного диабета 2 типа |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
AU2012300978B2 (en) | 2011-08-29 | 2017-04-27 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for use in glycemic control in diabetes type 2 patients |
AR087744A1 (es) | 2011-09-01 | 2014-04-16 | Sanofi Aventis Deutschland | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa |
US20150086622A1 (en) * | 2012-04-18 | 2015-03-26 | Nutrinia Ltd. | Growth enhancement of infants |
US20150209412A1 (en) | 2012-05-31 | 2015-07-30 | Nutrinia Ltd. | Insulin-containing infant formula |
TWI780236B (zh) | 2013-02-04 | 2022-10-11 | 法商賽諾菲公司 | 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物 |
EP2983661B1 (en) | 2013-04-09 | 2024-05-29 | Lixte Biotechnology, Inc. | Formulations of oxabicycloheptanes and oxabicycloheptenes |
MX2016008979A (es) | 2014-01-09 | 2016-10-04 | Sanofi Sa | Formulaciones farmaceuticas estabilizadas de analogos de insulina y/o derivados de insulina. |
RU2016132340A (ru) | 2014-01-09 | 2018-02-14 | Санофи | Стабилизированные фармацевтические составы на основе инсулина аспарта |
CA2932875A1 (en) | 2014-01-09 | 2015-07-16 | Sanofi | Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives |
HUE062573T2 (hu) | 2014-12-12 | 2023-11-28 | Sanofi Aventis Deutschland | Glargin inzulin/lixiszenatid rögzített arányú készítmény |
TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患治療 |
TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患之治療 |
US10039805B1 (en) | 2016-02-26 | 2018-08-07 | Michelle Ann Toothman | Infant formulas having vitamin complexes with enhanced bioavailability |
US11122833B1 (en) | 2016-02-26 | 2021-09-21 | Michelle Ann Toothman | Infant formulas having vitamin complexes with enhanced bioavailability |
US10617700B1 (en) | 2016-02-26 | 2020-04-14 | Michelle Ann Toothman | Vitamin supplement compositions with enhanced bioavailability |
RS64623B1 (sr) | 2016-03-24 | 2023-10-31 | Elgan Pharma Ltd | Upotreba insulina za podsticanje pražnjenja želuca |
ES2973984T3 (es) * | 2017-06-12 | 2024-06-25 | Elgan Pharma Ltd | Granulado multiparticulado que comprende insulina |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0795850A (ja) * | 1993-06-14 | 1995-04-11 | Snow Brand Milk Prod Co Ltd | 乳児用調製乳 |
JPH07223939A (ja) * | 1993-12-22 | 1995-08-22 | Bristol Myers Squibb Co | ミオイノシトールを含有する糖尿病治療剤および栄養組成物 |
JPH10146166A (ja) * | 1996-11-18 | 1998-06-02 | Nippon Shuzo Kumiai Chiyuuoukai | 生理活性組成物 |
JP2000503531A (ja) * | 1995-12-27 | 2000-03-28 | ミディア リミテッド | 非ヒト哺乳動物由来のベータカゼインを実質的に含まない乳から誘導された生産物及び関連する使用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4944944A (en) * | 1987-11-19 | 1990-07-31 | Oklahoma Medical Research Foundation | Dietary compositions and methods using bile salt-activated lipase |
JP3247206B2 (ja) * | 1993-06-11 | 2002-01-15 | 明治乳業株式会社 | ミルク組成物 |
JPH08214775A (ja) * | 1995-02-16 | 1996-08-27 | Meiji Milk Prod Co Ltd | アミノ酸組成を人乳に類似させた育児用乳製品 |
JP3985035B2 (ja) * | 1995-09-14 | 2007-10-03 | 独立行政法人産業技術総合研究所 | (n−6)系ドコサペンタエン酸含有油脂ならびに該油脂の製造方法および用途 |
-
1999
- 1999-06-03 WO PCT/US1999/012594 patent/WO1999062558A1/en active IP Right Grant
- 1999-06-03 EP EP99927267A patent/EP1083930B1/en not_active Expired - Lifetime
- 1999-06-03 AU AU44212/99A patent/AU762626B2/en not_active Expired
- 1999-06-03 ES ES99927267T patent/ES2320715T3/es not_active Expired - Lifetime
- 1999-06-03 AT AT99927267T patent/ATE413889T1/de not_active IP Right Cessation
- 1999-06-03 CA CA2334222A patent/CA2334222C/en not_active Expired - Lifetime
- 1999-06-03 JP JP2000551812A patent/JP2002516880A/ja active Pending
- 1999-06-03 DE DE69939900T patent/DE69939900D1/de not_active Expired - Lifetime
- 1999-06-03 US US09/701,652 patent/US6365177B1/en not_active Expired - Lifetime
-
2000
- 2000-12-04 IL IL140089A patent/IL140089A/en not_active IP Right Cessation
-
2012
- 2012-01-06 JP JP2012001306A patent/JP5188631B2/ja not_active Expired - Lifetime
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0795850A (ja) * | 1993-06-14 | 1995-04-11 | Snow Brand Milk Prod Co Ltd | 乳児用調製乳 |
JPH07223939A (ja) * | 1993-12-22 | 1995-08-22 | Bristol Myers Squibb Co | ミオイノシトールを含有する糖尿病治療剤および栄養組成物 |
JP2000503531A (ja) * | 1995-12-27 | 2000-03-28 | ミディア リミテッド | 非ヒト哺乳動物由来のベータカゼインを実質的に含まない乳から誘導された生産物及び関連する使用 |
JPH10146166A (ja) * | 1996-11-18 | 1998-06-02 | Nippon Shuzo Kumiai Chiyuuoukai | 生理活性組成物 |
Also Published As
Publication number | Publication date |
---|---|
WO1999062558A1 (en) | 1999-12-09 |
EP1083930A1 (en) | 2001-03-21 |
ES2320715T3 (es) | 2009-05-27 |
JP5188631B2 (ja) | 2013-04-24 |
US6365177B1 (en) | 2002-04-02 |
CA2334222A1 (en) | 1999-12-09 |
CA2334222C (en) | 2010-02-09 |
ATE413889T1 (de) | 2008-11-15 |
DE69939900D1 (de) | 2008-12-24 |
AU762626B2 (en) | 2003-07-03 |
EP1083930B1 (en) | 2008-11-12 |
EP1083930A4 (en) | 2005-01-12 |
JP2002516880A (ja) | 2002-06-11 |
IL140089A (en) | 2006-06-11 |
AU4421299A (en) | 1999-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5188631B2 (ja) | インスリンを補った乳児用調製乳 | |
Rangel et al. | Lactose intolerance and cow's milk protein allergy | |
Barbezat et al. | The exocrine pancreas and protein-calorie malnutrition | |
Rudloff et al. | Protein and nonprotein nitrogen components in human milk, bovine milk, and infant formula: quantitative and qualitative aspects in infant nutrition | |
Hambidge | Zinc deficiency in man: its origins and effects | |
AU2005332128B2 (en) | Food composition for stimulating growth comprising fraction isolated from mammalian colostrum or milk whey | |
US6399090B1 (en) | Insulin supplemented infant formula | |
CN100382796C (zh) | 用于提供谷氨酰胺的方法和组合物 | |
Prasad | Zinc in human nutrition | |
Kitts et al. | Adverse reactions to food constituents: allergy, intolerance, and autoimmunity | |
Kinouchi et al. | Large molecule protein feeding during the suckling period is required for the development of pancreatic digestive functions in rats | |
AU2013250712B9 (en) | Growth enhancement of infants | |
Donovan et al. | Partition of nitrogen intake and excretion in low-birth-weight infants | |
AU2013250712A1 (en) | Growth enhancement of infants | |
JP3979543B2 (ja) | 抗アレルギー剤及びその製造法 | |
Calvez et al. | Minimal processed infant formula vs. conventional shows comparable protein quality and increased postprandial plasma amino acid kinetics in rats | |
Sadler et al. | Beta-casein proteins and infant growth and development | |
HIPPE | Malabsorption of Vitamin B12: Report of a Case in a 1‐Year‐old Boy, Including Studies of the Absorption of B12 | |
Saba et al. | An overview of A1 and A2 Milk and its impact on Human Health | |
JP3556757B2 (ja) | 吸収促進性糖類組成物 | |
Littlewood et al. | Nutrition in cystic fibrosis | |
Munro | Report of a conference on protein and amino acid needs for growth and development | |
Keith et al. | Utilization of amino acids administered enterally or parenterally to young pigs | |
Macdonald | Clinical effects of consuming milk and its products | |
MCCRACKEN | VOl. 43 Meeting of 24 April 1984 I o9A |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120126 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120126 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120227 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20121217 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20121225 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130122 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160201 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5188631 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |